Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Lorenzo Gerratana; Qiang Zhang; Ami Naimish Shah; Andrew Adam Davis; Youbin Zhang; Firas Wehbe; Wenan Qiang; Lisa Flaum; Brian Steven Finkelman; William John Gradishar; Leonidas C Platanias; Amir Behdad; Massimo Cristofanilli

doi:10.1016/j.critrevonc.2019.102856

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Crit Rev Oncol Hematol. 2020 Jan:145:102856. doi: 10.1016/j.critrevonc.2019.102856. Epub 2019 Dec 23.

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Medicine (DAME), University of Udine, P.le Kolbe 4, 33100 Udine (UD), Italy.
² Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³ Department of Preventive Medicine, Division of Health and Biomedical Informatics, Northwestern University, Chicago, IL, USA.
⁴ Department of Pathology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
⁵ Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: massimo.cristofanilli@nm.org.

PMID: 31884205
DOI: 10.1016/j.critrevonc.2019.102856

Abstract

Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS™ and to compare its results with the clinically available Guardant360™ platform for possible analytical inconsistencies. The study suggests that PredicinePLUS™ NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met.

Keywords: Circulating tumor DNA; Clinical utility; Next generation sequencing; Precision medicine.

Publication types

Review

MeSH terms

Biomarkers, Tumor*
Breast Neoplasms* / diagnosis
Breast Neoplasms* / genetics
Circulating Tumor DNA*
Genomics
High-Throughput Nucleotide Sequencing*
Humans
Mutation

Substances

Biomarkers, Tumor
Circulating Tumor DNA